News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Announces Agreement With the PATH Malaria Vaccine Initiative



3/23/2009 10:00:24 AM

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals (VGX), a developer of DNA vaccines and therapies against cancer and infectious diseases, announced today an agreement with the PATH Malaria Vaccine Initiative (MVI) to evaluate in a preclinical feasibility study VGX’s SynCon™ DNA vaccine development platform. More specifically, VGX will design and test DNA vaccine candidates using target antigens from Plasmodium species and deliver them intradermally using the CELLECTRA® constant current electroporation device. The collaboration brings together vaccine development and malaria experts from the University of Pennsylvania School of Medicine and VGX.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES